一个用于多目标治疗的状纳米复合体,以缓解神经病理学和拯救阿尔茨海默氏症认知缺陷
Huarong Tan1,2, Yuqi Huang1, Shuqing Dong1
1Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Jiangsu, 221002, P. R. China.
Small (Weinheim an der Bergstrasse, Germany)
|August 27, 2023
概括
一种新性纳米材料,MSP-U,通过促进神经干细胞分化和清除β-粉样蛋白斑块,对阿尔茨海默病 (AD) 治疗具有前景. 这种创新材料可以在体内增强认知功能和记忆力.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 神经科学是一个神经科学.
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,治疗选择有限,以炎症和β-粉样蛋白 (Aβ) 斑块为特征.
- 性纳米材料由于其生物相容性和反原体选择性,为神经退行性疾病提供了潜在的治疗益处.
研究的目的:
- 开发一种对刺激有反应的性纳米材料,UiO-66-NH2 @l-MoS2 QDs@PA-Ni (MSP-U),用于阿尔茨海默病的治疗.
- 研究MSP-U刺激神经干细胞 (NSC) 分化,促进 (H2) 生产和清除Aβ斑块的能力.
主要方法:
- 开发采用l-MoS2量子点 (QD) 和植物酸 (PA-Ni) 的MSP-U.
- 利用循环极化近红外辐射来增强NSC差异化和PA-Ni通过光催化H2生产来进行反应性氧物种清理.
- 使用UiO-66金属氧化物来抑制电子孔重组,以提高H2生产效率和光热效应来清除Aβ斑块.
主要成果:
- MSP-U有效地刺激NSC分化为神经元,并促进H2生产.
- 该材料证明了有效地清除活性氧物种和清除Aβ斑块.
- 在体内研究表明MSP-U显著改善空间认知和记忆.
结论:
- MSP-U是一种有前途的刺激反应性性纳米材料,用于阿尔茨海默氏症治疗.
- 该材料的多方面的方法,包括神经再生和斑块清除,提供了一个新的治疗策略.
- 对奇拉纳米材料的进一步研究有可能用于治疗神经退行性疾病.
相关概念视频
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
151
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
151
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517


